• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

患有动脉粥样硬化性心血管疾病和2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂的相关因素：来自退伍军人事务部的见解

Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs.

作者信息

Al Rifai Mahmoud, Mahtta Dhruv, Ramsey David J, Lee Michelle T, Krittanawong Chayakrit, Navaneethan Sankar D, Gregg L Parker, Petersen Laura A, Virani Salim S

机构信息

Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX.

Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX; Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.

出版信息

Am Heart J. 2022 Jun;248:160-162. doi: 10.1016/j.ahj.2021.12.006. Epub 2021 Dec 27.

DOI:10.1016/j.ahj.2021.12.006
PMID:34968441
Abstract

This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

摘要

本研究利用退伍军人事务部（VA）的行政和临床数据集，调查了伴有动脉粥样硬化性心血管疾病（ASCVD）和糖尿病的患者使用钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）的决定因素。本分析的目的是在当代真实世界患者群体中确定与SGLT-2i相关的障碍和促进因素，以提高这些指南指导药物的使用率。

相似文献

1
Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs.患有动脉粥样硬化性心血管疾病和2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂的相关因素：来自退伍军人事务部的见解
Am Heart J. 2022 Jun;248:160-162. doi: 10.1016/j.ahj.2021.12.006. Epub 2021 Dec 27.
2
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.钠-葡萄糖共转运蛋白 2 抑制剂：对动脉粥样硬化和动脉粥样硬化性心血管疾病事件的影响。
Heart Fail Clin. 2022 Oct;18(4):597-607. doi: 10.1016/j.hfc.2022.03.007.
3
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.SGLT2 抑制剂在 2 型糖尿病、心力衰竭和动脉粥样硬化性心血管疾病患者中的使用率：来自退伍军人事务部的观察。
JACC Heart Fail. 2023 Aug;11(8 Pt 1):933-942. doi: 10.1016/j.jchf.2023.03.024. Epub 2023 May 17.
4
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的应用与心原性猝死和全因死亡风险。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):18-25. doi: 10.1093/ehjcvp/pvac043.
5
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.2型糖尿病患者中与钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂及其他降糖药物相关的心血管结局：一项真实世界的系统评价和荟萃分析
PLoS One. 2021 Feb 19;16(2):e0244689. doi: 10.1371/journal.pone.0244689. eCollection 2021.
6
Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs).基于退伍军人事务部的研究，探讨动脉粥样硬化性心血管疾病合并 2 型糖尿病患者使用胰高血糖素样肽-1 受体激动剂的相关因素。
Am J Cardiol. 2022 Jun 1;172:7-10. doi: 10.1016/j.amjcard.2022.02.013. Epub 2022 Mar 17.
7
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.SGLT-2 抑制剂与其他降血糖药物相关的心血管事件：CVD-REAL 2 研究。
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
8
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis.钠-葡萄糖共转运蛋白 2 抑制剂对动脉粥样硬化的抗炎作用。
Vascul Pharmacol. 2020 Oct-Nov;133-134:106779. doi: 10.1016/j.vph.2020.106779. Epub 2020 Aug 16.
9
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.钠-葡萄糖共转运蛋白 2 抑制剂在无心血管和肾脏疾病的日本 2 型糖尿病患者中的使用与较低的心衰和慢性肾脏疾病风险相关。
Diabetes Obes Metab. 2021 Apr;23 Suppl 2:19-27. doi: 10.1111/dom.14119.
10
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.当代 2 型糖尿病患者新型心脏保护降血糖药物的资格和使用的国家模式。
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. doi: 10.1161/JAHA.121.021084. Epub 2021 May 15.

引用本文的文献

1
Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.医疗服务不足人群中与钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂处方相关的合并症和邻里因素。
J Manag Care Spec Pharm. 2023 Jun;29(6):699-711. doi: 10.18553/jmcp.2023.29.6.699.
2
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.预测因素、差异和医疗机构间的差异：美国慢性肾脏病退伍军人中 SGLT2 抑制剂的处方情况。
Am J Kidney Dis. 2023 Jul;82(1):53-62.e1. doi: 10.1053/j.ajkd.2022.11.017. Epub 2023 Jan 23.